Collection contents
Lupus nephritis · For patients · Chapter 12
Pregnancy and reproductive plans: start the conversation early
Planning around kidney activity, medicines, fertility and postpartum care makes decisions clearer before pregnancy begins.
Open accessOn this page
Lupus nephritis does not automatically rule out pregnancy. It does make timing, kidney function, blood pressure and medication choices especially important. The most useful conversation often happens before you are ready to try: there may be time to establish stable control and replace a pregnancy-incompatible medicine without leaving the kidneys unprotected.
Why the quieter period matters
Active nephritis raises risks for both the pregnant person and the pregnancy. KDIGO advises avoiding planned conception during active nephritis and waiting at least six months after kidney disease becomes inactive. This is a starting point for discussion, not a guarantee that six months makes every pregnancy low-risk. Persistent kidney impairment, hypertension, previous complications and other lupus manifestations also matter.
Ask how your team will document stability. “I feel well” is encouraging, but the assessment also uses urine protein, kidney function, blood pressure and the treatment needed to maintain control. A preconception visit should ideally involve rheumatology, nephrology and an obstetric specialist experienced in high-risk pregnancy.
Review every medicine before trying
Mycophenolate can cause pregnancy loss and serious birth defects. It requires effective pregnancy prevention and a planned transition when pregnancy is desired. Cyclophosphamide and several kidney-protective medicines also require special review. The waiting interval after stopping a drug is drug-specific; do not apply a single “washout” period to the entire medication list.
Some treatments can be used during pregnancy when needed, including hydroxychloroquine and, in appropriate circumstances, azathioprine, tacrolimus, cyclosporine and glucocorticoids. “Pregnancy-compatible” does not mean interchangeable or suitable at any dose. The goal is a regimen that controls your disease and fits pregnancy, with time to check stability after a change.
If pregnancy occurs unexpectedly, contact the prescribing team promptly for an urgent medication review, especially if you take mycophenolate. Do not stop all treatment together or wait for a routine appointment. The team needs the drug names, doses, last doses and estimated pregnancy timing to plan the next steps.
Medication-specific pregnancy precautions
Mycophenolate: the US label requires acceptable contraception during treatment and for six weeks afterward for someone who can become pregnant. It may reduce oral contraceptive effectiveness; an additional barrier method is recommended. Sexually active men and/or their partners should use effective contraception during treatment and for at least 90 days afterward. Discuss pregnancy tests and a safe replacement before trying to conceive.
Cyclophosphamide: do not assume a three-month interval is sufficient. Current US labeling advises effective contraception for women during treatment and up to one year afterward, and for men during treatment and at least four months afterward. Your prescriber must check the actual product and reproductive plan.
ACE inhibitors and ARBs can harm a developing baby. Arrange a pregnancy-compatible blood-pressure plan. The US mycophenolate REMS program ended on July 29, 2026; that change did not remove the drug’s fetal risks or contraception precautions.
Contraception and fertility are separate questions
Discuss reliable contraception while pregnancy is not planned. Choices depend on clotting risk, antiphospholipid antibodies, blood pressure and medicines; not every hormonal method is appropriate for everyone. Mycophenolate has specific pregnancy-prevention requirements.
Cyclophosphamide can affect future fertility. Before treatment, discuss preservation options when time and disease severity allow. This conversation matters for women and men, and should not be postponed until the course is finished. Medication advice for someone who may become pregnant is not automatically the same as advice for a male partner taking treatment.
During pregnancy and after birth
Monitoring may include tests for antiphospholipid and anti-Ro/SSA or anti-La/SSB antibodies because the results can change the obstetric plan. US ACOG guidance recommends low-dose aspirin, usually 81 mg daily, for pregnancies with lupus or kidney disease, unless contraindicated. It is started from 12 weeks, ideally before 16 weeks; agree the prescription and timing with your obstetric clinician rather than starting it yourself.
New proteinuria, hypertension or kidney changes during pregnancy can reflect nephritis, preeclampsia or both. They require assessment rather than assumptions. Severe headache, visual disturbance, upper abdominal pain or breathlessness warrant urgent obstetric advice; severe or rapidly worsening symptoms require emergency care.
Plan postpartum follow-up, medication continuity, breastfeeding compatibility and practical support before delivery. A treatment that fits pregnancy may need a separate breastfeeding assessment. The objective is not merely to reach delivery: it is to protect kidney health while supporting your reproductive choices over time.
Sources and further reading
- KDIGO — Lupus Nephritis Guideline (2024)
- American College of Rheumatology — Pregnancy and Rheumatic Disease
- Sammaritano et al. — ACR Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology, 2020
- American College of Rheumatology — Cyclophosphamide
- NHS — Preeclampsia
- Genentech — CellCept: US Prescribing Information, revised July 2026
- DailyMed — Cyclophosphamide Tablets: US Prescribing Information
- Mycophenolate REMS — Program Discontinuation, July 29, 2026
- CDC HEAR HER — Urgent Maternal Warning Signs and Symptoms
- ACOG / SMFM — Low-Dose Aspirin for Prevention of Preeclampsia, 2021 Practice Advisory